drugset / Trial / NCT05019690
Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm,exploratory clinical study, to evaluate the effectiveness and safety of apatinib mesylate combined with albumin-bound paclitaxel for second-line treatment of advanced triple negative breast cancer.
Timeline
- Start
- 2021-10-01
- Primary completion
- 2024-12-01
- Completion
- 2025-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |